23 research outputs found

    Modulation of Voltage-Gated N-Type Calcium Channels by G Protein-Coupled Receptors Involves Lipids and Proteins: A Dissertation

    Get PDF
    Pain signaling involves transmission of nociceptive stimuli in the spinal cord where a critical balance between excitatory and inhibitory inputs determines the response to noxious stimuli. The neuropeptide, substance P (SP), mediates transmission of pain in part by binding to the tachykinin receptor (NK-1R) in the dorsal horn (DH) of the spinal cord. One of SPā€™s downstream effects is to modulate N-type Ca2+(N-) channels. While phospholipid breakdown is a part of the inflammatory process that accompanies tissue damage, the role of this metabolic pathway has not been completely described with respect to N-channel modulation during pain signaling. Despite the incomplete understanding of this modulation, pharmacological antagonists of both NK-1R and N-channels have been used to treat pain. In Chapter II, using whole-cell patch clamp recording techniques, the SP signaling cascade that mediates inhibition of recombinant N-channel activity was characterized. By adopting a pharmacological approach, I show that this pathway resembles the slow pathway that was earlier described for modulation of N-current by the M1 muscarinic receptor (M1R). M1R couples to Gq to stimulate phospholipid breakdown. Together with previous observations, the data presented in this chapter provide evidence for involvement of the extracellular receptor kinase (ERK1/2), phospholipase A2 and release of phospholipid metabolites in the modulation of N-current by SP. Overall, this chapter shows that phospholipid metabolism involved in modulation of N-currents is not specific to M1Rs but that other Gq-coupled receptors may also modulate N-currents via the same signal transduction pathway. In Chapter III, enhancement of N-current by SP was studied as part of a collaborative project to understand current enhancement that occurs when a palmitoylated accessory CaVĪ²2a subunit is co-expressed with the pore-forming subunit CaV2.2 and the accessory subunit Ī±2Ī“-1. When CaVĪ²3 is present, SP inhibits N-current as described in Chapter II. However, when palmitoylated CaVĪ²2a is co-expressed with CaV2.2 (and Ī±2Ī“-1), current enhancement is observed at negative test potentials, demonstrating that both M1Rs and NK-1Rs exhibit the same profile of N-current modulation. This change in modulation by muscarinic agonists is not observed in the presence of a depalmitoylated CaVĪ²2a. However a chimeric CaVĪ²2aĪ²1b subunit that contains the palmitoylated N-terminus from CaVĪ²2a confers enhancement. Normally expression of the Ī²1b subunit resulted in current inhibition. These findings indicated that the palmitoylated CaVĪ²2a participates in enhancement of current. Our data support a model where inhibition dominates over enhancement; when inhibition is blocked, enhancement may be observed. Lastly, we show that N-current inhibition by SP is minimized when exogenous palmitic acid is applied to cells co-expressing CaVĪ²3 subunits with N-channels. These results indicate that the presence of palmitic acid can prevent N-current inhibition when SP is applied most likely by interacting with CaV2.2. We propose a model where palmitic acid occupies the inhibitory site and serves to antagonize inhibition by a lipid metabolite, which is most likely arachidonic acid. The CaVĪ²2a protein seems to have a role in positioning the palmitoyl groups near CaV2.2. This chapter provides a new role for protein palmitoylation where the palmitoyl groups of CaVĪ²2a are both necessary and sufficient to block inhibition of another protein: CaV2.2. In Chapter IV, I probe the role of the relative orientation of CaVĪ²2a and the pore-forming subunit of the N-channel in N-current modulation. Evidence is presented that shows that not just the presence of a palmitoylated CaVĪ²2a is necessary, but the relative orientation of CaVĪ²2a to CaV2.2 is critical for blocking inhibition. Using N-channel mutants that cause a change in the orientation of CaVĪ²2a relative to CaV2.2, I show that the block of inhibition is disrupted; inhibition by the slow pathway is rescued. These findings further support my model that the palmitoyl groups of CaVĪ²2a normally reside in a specific location that overlaps with the slow pathway inhibitory site on CaV2.2. Lastly I present data showing that the enhancement of N-current, observed when palmitoylated CaVĪ²2a is present, occurs via the slow pathway. In Chapter V the effect of CaVĪ²ā€™s orientation on N-channel modulation by the dopamine D2 receptor is tested. In this form of modulation, inhibition is rapid and voltage-dependent. The signaling pathway is membrane-delimited since GĪ²Ī³, released after receptor stimulation, directly interacts with the N-channel at a site that overlaps with a high affinity binding site for CaVĪ²s. While N-currents are modulated by this pathway, the deletion mutants show aberrant membrane-delimited modulation. The findings in this chapter further underscore the importance of proper positioning of CaVĪ² to CaV2.2 for eliciting proper N-current modulation after GPCR stimulation. Overall, the data presented in this dissertation provides a mechanistic approach into examining modulation of N-current by different GPCRs via two different signaling pathways as well as the role CaVĪ² subunits serve in each modulatory pathway

    Orientation of palmitoylated CaVĪ²2a relative to CaV2.2 is critical for slow pathway modulation of N-type Ca2+ current by tachykinin receptor activation

    Get PDF
    The Gq-coupled tachykinin receptor (neurokinin-1 receptor [NK-1R]) modulates N-type Ca2+ channel (CaV2.2 or N channel) activity at two distinct sites by a pathway involving a lipid metabolite, most likely arachidonic acid (AA). In another study published in this issue (Heneghan et al. 2009. J. Gen Physiol. doi:10.1085/jgp.200910203), we found that the form of modulation observed depends on which CaVĪ² is coexpressed with CaV2.2. When palmitoylated CaVĪ²2a is coexpressed, activation of NK-1Rs by substance P (SP) enhances N current. In contrast, when CaVĪ²3 is coexpressed, SP inhibits N current. However, exogenously applied palmitic acid minimizes this inhibition. These findings suggested that the palmitoyl groups of CaVĪ²2a may occupy an inhibitory site on CaV2.2 or prevent AA from interacting with that site, thereby minimizing inhibition. If so, changing the orientation of CaVĪ²2a relative to CaV2.2 may displace the palmitoyl groups and prevent them from antagonizing AA's actions, thereby allowing inhibition even in the presence of CaVĪ²2a. In this study, we tested this hypothesis by deleting one (Bdel1) or two (Bdel2) amino acids proximal to the Ī± interacting domain (AID) of CaV2.2's Iā€“II linker. CaVĪ²s bind tightly to the AID, whereas the rigid region proximal to the AID is thought to couple CaVĪ²'s movements to CaV2.2 gating. Although Bdel1/Ī²2a currents exhibited more variable enhancement by SP, Bdel2/Ī²2a current enhancement was lost at all voltages. Instead, inhibition was observed that matched the profile of N-current inhibition from CaV2.2 coexpressed with CaVĪ²3. Moreover, adding back exogenous palmitic acid minimized inhibition of Bdel2/Ī²2a currents, suggesting that when palmitoylated CaVĪ²2a is sufficiently displaced, endogenously released AA can bind to the inhibitory site. These findings support our previous hypothesis that CaVĪ²2a's palmitoyl groups directly interact with an inhibitory site on CaV2.2 to block N-current inhibition by SP

    The Ca2+ channel beta subunit determines whether stimulation of Gq-coupled receptors enhances or inhibits N current

    Get PDF
    In superior cervical ganglion (SCG) neurons, stimulation of M(1) receptors (M(1)Rs) produces a distinct pattern of modulation of N-type calcium (N-) channel activity, enhancing currents elicited with negative test potentials and inhibiting currents elicited with positive test potentials. Exogenously applied arachidonic acid (AA) reproduces this profile of modulation, suggesting AA functions as a downstream messenger of M(1)Rs. In addition, techniques that diminish AA\u27s concentration during M(1)R stimulation minimize N-current modulation. However, other studies suggest depletion of phosphatidylinositol-4,5-bisphosphate during M(1)R stimulation suffices to elicit modulation. In this study, we used an expression system to examine the physiological mechanisms regulating modulation. We found the beta subunit (Ca(V)beta) acts as a molecular switch regulating whether modulation results in enhancement or inhibition. In human embryonic kidney 293 cells, stimulation of M(1)Rs or neurokinin-1 receptors (NK-1Rs) inhibited activity of N channels formed by Ca(V)2.2 and coexpressed with Ca(V)beta1b, Ca(V)beta3, or Ca(V)beta4 but enhanced activity of N channels containing Ca(V)beta2a. Exogenously applied AA produced the same pattern of modulation. Coexpression of Ca(V)beta2a, Ca(V)beta3, and Ca(V)beta4 recapitulated the modulatory response previously seen in SCG neurons, implying heterogeneous association of Ca(V)beta with Ca(V)2.2. Further experiments with mutated, chimeric Ca(V)beta subunits and free palmitic acid revealed that palmitoylation of Ca(V)beta2a is essential for loss of inhibition. The data presented here fit a model in which Ca(V)beta2a blocks inhibition, thus unmasking enhancement. Our discovery that the presence or absence of palmitoylated Ca(V)beta2a toggles M(1)R- or NK-1R-mediated modulation of N current between enhancement and inhibition identifies a novel role for palmitoylation. Moreover, these findings predict that at synapses, modulation of N-channel activity by M(1)Rs or NK-1Rs will fluctuate between enhancement and inhibition based on the presence of palmitoylated Ca(V)beta2a

    Proceedings of the workshop ā€˜Biofortified food - Working together to get more nutritious food to the table in Indiaā€™

    No full text
    HarvestPlus is the global leader in biofortification and has been leading biofortification efforts in India for nearly a decade. A workshop hosted by HarvestPlus was held in April 2019 in New Delhi to discuss ways to increase the scale, reach and impact of naturally nutritious (biofortified) foods in India by working in partnership with the food industry. This paper summarizes the output of that 2-day workshop. Harvest Plus is a not-for-profit organization that works with its partners to tackle hidden hunger and malnutrition. It leads the global effort to develop biofortified staple crops, explore their acceptability, efficacy and effectiveness, and scale up their availability to rural and urban populations who may not have access to diverse diet, fortified foods or supplements. Scaling the reach and impact of biofortified food through foods systems is a key strategy for HarvestPlus. In this regard, HarvestPlus has conducted research into the barriers for scale-up and co-created solutions to overcoming those barriers through partnership with the food industry. During this workshop, it emerged that there is significant demand from the food industry who see value in biofortification to both their business and the health of their customers and the country. Small working groups explored specific opportunities around supply chains, food products and composition, and consumers & markets. Several common themes emerged from the deliberations. All three groups identified lack of awareness as a major barrier to scale. More data on the health and nutrition impacts, as well as consumer and market research, is critically needed to build the food industryā€™s understanding of biofortified foods. Ensuring supply chain integrity, meeting manufacturing product standards, and developing strategic messaging for consumers were also mentioned repeatedly. Ending hidden hunger and managing a profitable food business can be done simultaneously and sustainably. By addressing the barriers to embedding biofortification into the food system, HarvestPlus aims to increase the access that families and communities have to nutritious seeds and foods.PRIFPRI3; CRP4; DCAHarvestPlus; A4NHCGIAR Research Program on Agriculture for Nutrition and Health (A4NH

    The global regulatory framework for the commercialization of nutrient enriched biofortified foods

    No full text
    Nutrient enriched crops (NECs) were developed through biofortification as a tool to reach the world's most vulnerable. The delivery model developed by HarvestPlus for the scaling of NECs relies on commercial demand from food businesses and consumers, coupled with the ability to promote and market foods that comply with legislation. This review of standards, regulations, and laws across the value chain in 20 countries demonstrates that existing provisions for food labeling are sufficient to carry out sales and marketing of foods made from conventionally bred NECs. The term biofortification is not necessary to create demand and, potentially, is counterproductive. Promoting the natural source of vitamins and minerals and relevant nutrition claims is the most effective and simple way to signpost healthier products to consumers. Until 2021, it was not possible to distinguish NECs at the grain level from the market standard. The development of a globally relevant Publicly Available Specification allows traders to demand grains that offer a substantial increase in zinc, iron, or vitamin A. Addressing this gap at the grain level ensures that standards and regulations are available end-to-end in the food supply chain providing the enabling environment for the rapid scale of NECs.PRIFPRI3; ISI; 1 Fostering Climate-Resilient and Sustainable Food Supply; 2 Promoting Healthy Diets and Nutrition for all; 3 Building Inclusive and Efficient Markets, Trade Systems, and Food Industry; 4 Transforming Agricultural and Rural Economies; Capacity Strengthening; HarvestPlusHarvestPlu

    Regulation of voltage-gated Ca2+ channels by lipids

    No full text
    Great skepticism has surrounded the question of whether modulation of voltage-gated Ca(2+) channels (VGCCs) by the polyunsaturated free fatty acid arachidonic acid (AA) has any physiological basis. Here we synthesize findings from studies of both native and recombinant channels where micromolar concentrations of AA consistently inhibit both native and recombinant activity by stabilizing VGCCs in one or more closed states. Structural requirements for these inhibitory actions include a chain length of at least 18 carbons and multiple double bonds located near the fatty acid\u27s carboxy terminus. Acting at a second site, AA increases the rate of VGCC activation kinetics, and in Ca(V)2.2 channels, increases current amplitude. We present evidence that phosphatidylinositol 4,5-bisphosphate (PIP(2)), a palmitoylated accessory subunit (beta(2a)) of VGCCs and AA appear to have overlapping sites of action giving rise to complex channel behavior. Their actions converge in a physiologically relevant manner during muscarinic modulation of VGCCs. We speculate that M(1) muscarinic receptors may stimulate multiple lipases to break down the PIP(2) associated with VGCCs and leave PIP(2)\u27s freed fatty acid tails bound to the channels to confer modulation. This unexpectedly simple scheme gives rise to unanticipated predictions and redirects thinking about lipid regulation of VGCCs

    A Randomized, Double-Blind Study Assessing Changes in Cognitive Function in Indian School Children Receiving a Combination of Bacopa monnieri and Micronutrient Supplementation vs. Placebo

    Get PDF
    Several studies have indicated a chronic cognitive enhancing effect of Bacopa monnieri across different ages and cognitive impairment associated with vitamin and mineral deficiencies in children. Therefore, we investigated the effects of 4-month supplementation with a combination of B. monnieri extract and multiple micronutrients on cognitive functions in Indian school children aged 7ā€“12 years. This was a randomized, double-blind, parallel design, single-center study in which 300 children were randomized to receive a beverage either fortified with B. monnieri and multiple micronutrients (ā€œfortifiedā€) or a non-fortified isocaloric equivalent (ā€œcontrolā€) twice-daily for 4 months. Cognitive function was assessed by the Cambridge Neuropsychological Automated Test Battery (CANTAB) administered at baseline, Day 60 and Day 121. The primary endpoint was change in short-term memory (working memory) from baseline in subjects receiving ā€œfortifiedā€ vs. ā€œcontrolā€ beverages after 4 months. Secondary endpoints included sustained attention, episodic memory, and executive function. The ā€œfortifiedā€ beverage did not significantly improve short-term memory or any of the secondary outcomes tested relative to the ā€œcontrolā€ beverage. However, the spatial working memory ā€œstrategyā€ score showed significant improvement on Day 60 (difference between groups in change from baseline: āˆ’0.55; p < 0.05), but not on Day 121 due to the active intervention. Study products were well-tolerated. Reasons for these unexpected findings are discussed
    corecore